Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

BLA FilingrejectedIfinatamab DeruxtecanNegative

AI Analysis

Summary

Daiichi Sankyo voluntarily withdrew the Biologics License Application for Ifinatamab Deruxtecan in previously treated extensive-stage small cell lung cancer. The withdrawal represents a regulatory setback for the candidate.

Outcome Details

Biologics License Application voluntarily withdrawn

Importance:7/10

Sentiment:

-0.80

BLA withdrawalsmall cell lung cancerregulatory setbackoncology

Related Companies

$DSKYF

Read the original article

Published by yahoo_finance on September 25, 2026 8:30 PM

Read Original